Here are some of the major companies whose stocks moved on the week’s news.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...